ONCOLYTICS BIOTECH INC | CIK:0001129928 | 3

  • Filed: 3/19/2018
  • Entity registrant name: ONCOLYTICS BIOTECH INC (CIK: 0001129928)
  • Generator: Workiva (WebFilings)
  • SEC filing page: http://www.sec.gov/Archives/edgar/data/1129928/000112992818000028/0001129928-18-000028-index.htm
  • XBRL Instance: http://www.sec.gov/Archives/edgar/data/1129928/000112992818000028/oncyf-20171231.xml
  • XBRL Cloud Viewer: Click to open XBRL Cloud Viewer
  • EDGAR Dashboard: https://edgardashboard.xbrlcloud.com/edgar-dashboard/?cik=0001129928
  • Open this page in separate window: Click

    • ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory

    Authorized:
    Unlimited number of no par value common shares
    Issued:
    Shares
    Warrants
     
    Number
    Amount
    $
    Number
    Amount
    $
    Balance, December 31, 2014
    93,512,494

    237,657,056

    —

    —

    Issued pursuant to Share Purchase
    Agreement    (a)
    5,778,674

    4,371,687

    —

    —

    Issued pursuant to "At the Market" sales agreement(b)
    18,860,454

    20,049,693

    —

    —

    Share issue costs
    —

    (753,744
    )
    —

    —

    Balance, December 31, 2015
    118,151,622

    261,324,692

    —

    —

    Issued pursuant to incentive share award plan
    100,000

    41,000

    —

    —

    Issued pursuant to "At the Market" equity distribution agreement(c)
    3,006,600

    1,456,296

    —

    —

    Share issue costs
    —

    (500,163
    )
    —

    —

    Balance, December 31, 2016
    121,258,222

    262,321,825

    —

    —

    Issued pursuant to stock option plan
    801,000

    536,949

    —

    —

    Issued pursuant to "At the Market" equity distribution agreement(c)
    3,301,500

    2,348,821

    —

    —

    Issued pursuant to public offering(d)
    16,445,000

    7,893,600

    16,445,000

    3,617,900

    Share issue costs
    —

    (1,391,057
    )
    —

    —

    Balance, December 31, 2017
    141,805,722

    271,710,138

    16,445,000

    3,617,900



    (a)
    In 2014, we entered into a share purchase agreement (the "Share Purchase Agreement") with Lincoln Park Capital Fund, LLC ("LPC") to sell up to US$26,000,000 of common stock. Subject to the terms and conditions of the Share Purchase Agreement and at our sole discretion, we may sell up to US$26.0 million worth of common shares to LPC over the 30-month term. The purchase price of the common shares was based on prevailing market prices of our common shares immediately preceding the notice of a sale without any fixed discount. Subject to the Share Purchase Agreement, we controlled the timing and amount of each investment and LPC was obligated to make such purchases, if and when elected. The Share Purchase Agreement did not impose any upper price limit restrictions, negative covenants or restrictions on our future financing activities, but required that we maintained our NASDAQ listing. Under the Share Purchase Agreement, we issued an initial commitment fee of 292,793 common shares to LPC valued at fair value of US$455,000. An additional 292,793 common shares was to be issued on a pro rata basis under the terms of the Share Purchase Agreement as an additional commitment fee.

    On October 20, 2014, we reached an agreement to amend the Share Purchase Agreement. The specific amendments included allowing the Company to sell shares to LPC at the Company's sole option independent of the closing price of the Common Stock, increasing the number of shares that may have been sold to LPC at certain price levels and changed the way the number of Commitment Shares issuable was to be calculated. In consideration of the amendments to the Agreement, the Company issued 146,397 shares of Common Stock to LPC.

    In 2015, under the terms of the amended Share Purchase Agreement, we issued 5,778,674 common shares for net proceeds of approximately US$3.5 million. As part of the shares issued, we issued 78,674 commitment shares. The commitment shares have been valued at fair value of US$50,024 and have been recorded as additional share issue costs. On November 5, 2015, we were delisted from the NASDAQ Capital Market and as a result we were unable to sell common shares under the Share Purchase Agreement.

    (b)
    On October 24, 2014, we entered into an "at-the-market" ("ATM") equity distribution agreement with Canaccord Genuity Inc. acting as sole agent. Under the terms of the distribution agreement, we were able to, from time to time, sell shares of our common stock having an aggregate offering value of up to US$20 million through Canaccord Genuity Inc. directly to investors in the US through our NASDAQ listing. We were able to determine, at our sole discretion, the timing and number of shares to be sold under this ATM facility. During 2015, we issued 18,860,454 common shares for net proceeds of approximately US$15.5 million. On November 5, 2015, we were delisted from the NASDAQ Capital Market and as a result we were unable to sell common shares under our existing ATM.

    (c)
    On February 25, 2016, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. acting as our sole agent with an aggregate offering value of up to $4.6 million which allows us to sell our common shares through the facilities of the Toronto Stock Exchange or other "marketplace” (as defined in National Instrument 21-101 Marketplace Operation) in Canada (our "Canadian ATM"). Subject to the terms of our Canadian ATM, we are able to determine, at our sole discretion, the timing and number of shares to be sold under this ATM facility. During 2017, we sold 3,301,500 (2016 - 3,006,600) common shares for gross proceeds of $2,348,821 (2016 - $1,456,296). We incurred share issue costs of $245,655 (2016 - $500,163).

    (d)
    On June 1, 2017, pursuant to an underwritten public offering, 16,445,000 units were sold at a purchase price of $0.70 per unit for gross proceeds of $11,511,500. Each unit included one common share (ascribed value of $0.48) and one common share purchase warrant (ascribed value of $0.22). The ascribed value was determined using the relative fair value method. The ascribed value of the common share purchase warrants was determined using the Black Scholes option pricing model. Each common share purchase warrant entitles the holder to purchase one common share in the capital of the Company until June 1, 2022, at an exercise price of $0.95. The common share purchase warrants will be subject to acceleration if the volume weighted average price of the Company's common shares equals or exceeds $2.50 for 15 consecutive trading dates. We incurred share issue costs of $1,145,402.